<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The Cox model is widely used in medical research for comparing survival </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0002665'>Lymphomas</z:hpo> might exhibit important differences in long-term cure rate despite a similar survival </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Using log-rank test, we compared event-free survival (EFS), and the survival of 64 patients with mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), 525 patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and 1136 patients with diffuse <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (CB) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Although EFS and survival of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> were significantly shorter than those of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, checking the validity of the proportional hazards assumption shows that the distribution of rates of events and <z:hpo ids='HP_0011420'>deaths</z:hpo> over time did not differ in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, the ratios of hazards (events and <z:hpo ids='HP_0011420'>deaths</z:hpo> rates) did not remain constant over time in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and CB, because of a decrease in late events and <z:hpo ids='HP_0011420'>deaths</z:hpo> rates in the latter histological type </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: Checking the validity of the Cox model hypothesis might be a useful tool for assessing long-term cure rate in seldom <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes </plain></SENT>
<SENT sid="6" pm="."><plain>Despite a short overall survival, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> should not be considered to be an aggressive <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, in which available chemotherapy may cure a subset of patients </plain></SENT>
</text></document>